Amiodarone is a powerful heart rhythm medication used primarily to treat life-threatening ventricular arrhythmias, specifically recurrent ventricular fibrillation and recurrent ventricular tachycardia that causes dangerously low blood pressure. It is also one of the most effective drugs for managing atrial fibrillation, particularly in people with heart failure. Because it carries significant risks, amiodarone is typically reserved for serious heart rhythm problems that haven’t responded to other treatments.
Life-Threatening Ventricular Arrhythmias
The FDA approved amiodarone specifically for two conditions: recurrent ventricular fibrillation (where the heart’s lower chambers quiver chaotically instead of pumping blood) and recurrent hemodynamically unstable ventricular tachycardia (where the lower chambers beat dangerously fast, causing blood pressure to drop). Both are medical emergencies that can lead to cardiac arrest within minutes.
The approval language is unusually restrictive. Amiodarone is indicated only when these arrhythmias have not responded to adequate doses of other antiarrhythmic drugs, or when a patient could not tolerate those alternatives. This narrow label reflects the drug’s serious side effect profile, which requires careful, ongoing monitoring.
In emergency settings, amiodarone is given intravenously during cardiac arrest or unstable heart rhythms. It is part of standard advanced cardiac life support protocols and is commonly administered in emergency rooms and intensive care units.
Atrial Fibrillation and Rhythm Control
Beyond its FDA-approved uses, amiodarone is widely used to restore and maintain a normal heart rhythm in people with atrial fibrillation, the most common type of irregular heartbeat. The 2023 guidelines from the American Heart Association and American College of Cardiology recommend it as a frontline option for patients who also have heart failure with reduced pumping ability, because most other rhythm-control drugs are unsafe in that population.
For people without heart failure, guidelines recommend trying other antiarrhythmic medications first and reserving amiodarone for cases where those drugs fail or aren’t tolerated. This isn’t because amiodarone doesn’t work well. It’s actually more effective than the alternatives. In the SAFE-T trial, the median time before atrial fibrillation returned was 487 days with amiodarone compared to just 74 days with another common drug. The Canadian Trial of Atrial Fibrillation found recurrence rates of 35% with amiodarone versus 63% with alternatives at 16 months. The tradeoff is that amiodarone’s side effects are more serious, so doctors weigh its superior rhythm control against the burden of long-term monitoring.
How It Works in the Body
Amiodarone stabilizes heart rhythm by affecting the electrical signals that coordinate each heartbeat. It works through multiple mechanisms at once, which is part of why it’s so broadly effective but also why it affects so many other organs.
One of the most unusual things about amiodarone is how long it stays in your body. After you stop taking it, the drug’s effects don’t disappear in a day or two. The average elimination half-life is about 53 days, meaning it takes roughly two months for just half the drug to leave your system. In some people, this extends well beyond 100 days. The drug accumulates in fat tissue, lung tissue, the liver, and other organs, which is why its effects, both therapeutic and harmful, can persist for weeks or months after the last dose.
Thyroid Problems
Amiodarone contains a large amount of iodine, roughly 37% of its weight. Since the thyroid gland uses iodine to make hormones, flooding the body with this much iodine can push thyroid function in either direction. Between 2% and 24% of patients develop thyroid abnormalities.
Some people develop an underactive thyroid, where the gland slows down in response to the iodine overload. Others develop an overactive thyroid, either because the excess iodine fuels hormone overproduction or because the drug directly damages thyroid cells, causing stored hormones to leak into the bloodstream. Both forms require treatment, and the overactive type can be especially difficult to manage because the drug’s long half-life means the iodine exposure continues long after amiodarone is stopped.
Lung Toxicity
Amiodarone-related lung damage affects an estimated 1% to 5% of patients, with higher rates at higher doses. It most commonly appears as interstitial pneumonitis, a type of inflammation in the lung tissue that typically develops after at least two months of therapy, especially at daily doses above 400 mg. When pulmonary toxicity occurs, it is fatal in roughly 10% of cases.
The challenge is that there’s no specific test for it. Doctors diagnose it by ruling out other causes like heart failure or infection. Symptoms include a new or worsening cough, shortness of breath, and sometimes fever, which is why baseline and periodic chest X-rays are part of the monitoring plan.
Liver Effects
Amiodarone can cause elevations in liver enzymes, which signal inflammation or damage to liver cells. In most cases, these elevations are mild and reversible, but rare cases of serious liver toxicity have been reported. Liver function blood tests are recommended at baseline and every six months during treatment.
Important Drug Interactions
Amiodarone significantly affects how the body processes several other common heart medications. It increases the blood-thinning effect of warfarin, sometimes enough to cause bleeding episodes. It also raises blood levels of digoxin, a drug used for heart failure and certain arrhythmias. If you take either of these medications, your doses will likely need to be reduced and monitored more closely when amiodarone is added.
Monitoring While on Amiodarone
Because the drug affects so many organ systems, regular testing is essential for anyone taking it long-term. The Heart Rhythm Society recommends baseline and every-six-month testing for both thyroid function and liver function. A chest X-ray is recommended at baseline and then annually, with additional imaging if respiratory symptoms develop. An eye exam is recommended at baseline for anyone with visual impairment and again if vision changes occur, since the drug can cause deposits on the cornea. An electrocardiogram to check the heart’s electrical timing is recommended at baseline and annually.
Who Should Not Take Amiodarone
Amiodarone is contraindicated in people with second- or third-degree heart block who do not have a pacemaker. In these conditions, electrical signals between the upper and lower chambers of the heart are partially or completely blocked, and amiodarone could worsen that blockage to the point where the heart rate drops dangerously low. Intravenous amiodarone also should not be used in patients with significant slowing of the heart rate (bradycardia) unless a pacemaker is in place to serve as a backup.